Processing...
Clinical Trials for Non-Small Cell Lung Cancer
Search
Search
There are 367 active trials for advanced/metastatic non-small cell lung cancer.
Click on a trial to see more information.
367 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Enrolls adults with relapsed/refractory locally advanced or metastatic solid tumors harboring a SMARCA4 loss-of-function mutation (ECOG 0–1, measurable disease) after progression on, intolerance of, or ineligibility for standard approved therapies. Patients receive oral once-daily PLX-61639, a SMARCA2 targeted protein degrader (synthetic-lethal strategy in SMARCA4-deficient tumors; DCAF16-linked, proteasome-mediated SMARCA2 degradation).
ClinicalTrials.gov ID: NCT07284186
TrialFetch AI summary: Enrolling adults (ECOG 0–1) with metastatic/unresectable solid tumors refractory to standard therapy (excluding melanoma, primary brain tumors/GBM, sarcoma, and pancreatic ductal adenocarcinoma; no active untreated brain mets), with expansion cohorts limited to ≤3 prior systemic lines and focused on PD-(L)1–naïve MSS colorectal cancer without liver metastases and PD-1 relapsed/refractory MSS endometrial cancer, RCC, or NSCLC. Patients receive IV ADU-1805 (anti-SIRPα mAb blocking the SIRPα–CD47 “don’t eat me” checkpoint to enhance myeloid/macrophage activity) every 3 weeks alone or with fixed-dose pembrolizumab every 3 weeks.
ClinicalTrials.gov ID: NCT05856981
TrialFetch AI summary: Adults with locally advanced unresectable or metastatic solid tumors harboring a KRAS alteration (mutation or amplification) who have progressed on, are ineligible for, or declined standard-of-care therapy (Arm D additionally requires PD-L1 TPS ≥50%; excludes untreated CNS metastases and ILD/pneumonitis). Participants receive the first-in-human agent BMS-986523 (target/mechanism not publicly described) as monotherapy or combined with pembrolizumab (anti–PD-1), cetuximab (anti-EGFR), or gemcitabine plus nab-paclitaxel.
ClinicalTrials.gov ID: NCT07223047
TrialFetch AI summary: Adults with locally advanced/metastatic measurable solid tumors harboring any KRAS mutation or wild-type KRAS amplification (ECOG 0–1) after 1–4 prior systemic regimens are treated with IV PT0511 monotherapy in dose-escalation/expansion cohorts; a colorectal cancer expansion cohort receives PT0511 plus cetuximab (anti-EGFR). PT0511 is an investigational KRAS-altered tumor–directed agent, but its specific molecular mechanism/allele selectivity is not publicly specified.
ClinicalTrials.gov ID: NCT07300150
TrialFetch AI summary: Adults with unresectable locally advanced/metastatic EGFR-mutant NSCLC (ECOG 0–1) with progression after prior first- or second-line osimertinib (alone or with chemotherapy), excluding those with other actionable drivers or known EGFR osimertinib-resistance mutations. Treatment is continued osimertinib plus escalating-dose oral NXP900 (eCF506), a selective SRC-family kinase inhibitor (high potency vs YES1; also SRC) designed to lock kinases in an inactive conformation to address resistance biology.
ClinicalTrials.gov ID: NCT07315113
TrialFetch AI summary: Enrolls adults with locally advanced/metastatic/unresectable solid tumors harboring ERBB2 (HER2) activating alterations, NRG1 fusions, or HER2 overexpression, with expansion cohorts for ERBB2-mutant NSCLC with brain metastases and ERBB2-mutant or HER2-overexpressing breast cancer with brain metastases ± leptomeningeal disease. Patients receive oral CGT4255, an investigational EGFR-sparing selective HER2 tyrosine kinase inhibitor designed to cover multiple oncogenic HER2 mutations with CNS penetration, given at escalating/selected doses.
ClinicalTrials.gov ID: NCT07361562
TrialFetch AI summary: Adults with ECOG 0–1 locally advanced unresectable or metastatic solid tumors (including NSCLC without actionable alterations, urothelial carcinoma, gastric/GEJ cancer, and HER2-negative breast cancer) in selected treatment settings, including 2L+ NSCLC and post–enfortumab vedotin+pembrolizumab urothelial carcinoma, plus first-line metastatic NSCLC (adenocarcinoma) and urothelial cohorts. Patients receive IV ASP2998, a first-in-human TROP2-targeting antibody–drug conjugate, as monotherapy or combined with pembrolizumab and/or carboplatin, and/or with enfortumab vedotin (urothelial cohorts), in 21-day cycles until progression or toxicity.
ClinicalTrials.gov ID: NCT07287995
TrialFetch AI summary: Enrolls adults with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors (including CRPC, NSCLC/SCLC, CRC, HNSCC, ovarian/cervical/endometrial cancers, TNBC, and esophageal SCC) who have progressed after their most recent therapy and have no suitable standard option, with ECOG 0–2 and adequate organ function (measurable disease required except in CRPC; prior Lu-177–PSMA excluded for CRPC). Patients receive 177Lu-BetaBart, a lutetium-177–labeled anti–B7-H3 (CD276) monoclonal antibody delivering beta-particle radiation as systemic radioimmunotherapy in a dose-escalation/expansion design.
ClinicalTrials.gov ID: NCT07189871
TrialFetch AI summary: Adults with metastatic/advanced NSCLC, gastroesophageal, colorectal, hepatocellular, pancreatic, or head and neck squamous cell carcinoma that has progressed on or is intolerant to standard systemic therapy (ECOG 0–2; measurable disease) receive DM005 (YH013) monotherapy IV Q3W. DM005 is a first-in-human bispecific antibody–drug conjugate targeting EGFR and c-MET, intended to preferentially bind EGFR/MET co-expressing tumors to enhance internalization and cytotoxic payload delivery, with dose escalation/expansion to define safety/MTD and assess preliminary activity.
ClinicalTrials.gov ID: NCT06515990
TrialFetch AI summary: This trial involves adults with unresectable locally advanced or metastatic NSCLC harboring active EGFR mutations, including C797S, who have progressed on osimertinib or another third-generation EGFR-TKI, receiving the investigational fourth-generation EGFR tyrosine kinase inhibitor H002 to assess its safety and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05519293